Pharmaceutical Executive July 25, 2025
The acquisition led by Advent International will see the two AI-powered companies combine forces to improve the healthcare payment system.
Waystar, in a deal led by global private equity investor Advent International, will acquire 100% of Iodine from shareholders. The transaction is funded by a fifty-fifty split between cash and stock considerations and provides Waystar shareholders 92% ownership of the combined company on a fully diluted pro forma basis, while Iodine equity holders will see approximately 8% of ownership.
Mike Kadyan, Co-Founder and Chairman of Iodine Software spoke on the impact of the acquisition, saying, “Our success has been driven by strong partnerships, continuous innovation, and meaningful outcomes. We look forward to delivering even greater outcomes for providers as...
Today's Sponsors
Today's Sponsor